Updated on 15/03/2018
REMICADE has over 18 years of experience of treating patients with immune-mediated diseases in the field of Rheumatology, Gastroenterology and Dermatology.
REMICADE, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in:
In these patient populations, a reduction in the rate of the progression of joint damage, as measured by X-ray, has been demonstrated (see section 5.1 of SmPC2).
REMICADE is indicated for:
REMICADE is indicated for treatment of severe, active Crohn's disease, in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. REMICADE has been studied only in combination with conventional immunosuppressive therapy.
REMICADE is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
REMICADE is indicated for treatment of severely active ulcerative colitis, in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies.
REMICADE is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have responded inadequately to conventional therapy.
REMICADE is indicated for treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.
REMICADE should be administered
REMICADE has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1 of SmPC2).
REMICADE is a monoclonal antibody; it is a TNFα (Tumour Necrosis Factor–alpha) inhibitor that is indicated for the treatment of a range of immune-mediated inflammatory disorders.2
REMICADE is a prescription-only product. It is presented as powder (100 mg/vial) to be reconstituted with water, diluted with saline and thereafter administered via intravenous infusion.2
REMICADE inhibits TNFα, thereby neutralising its biological activity.
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet
MULT-1246521-0000 | Date of Preparation: March 2018